IDH2 and glioblastoma: A retrospective study (26) of 453 IDH-wildtype glioblastoma patients found that tumors harboring both MGMT methylation and TERT mutations exhibited the longest survival, whereas MGMT-unmethylated/TERT-mutated tumors had the poorest outcomes, suggesting a potential synergistic interaction between these molecular alterations.